| Literature DB >> 36235298 |
Kindi Farabi1, Desi Harneti1, Tri Mayanti1, Rani Maharani1,2, Aprilia Permata Sari1, Tati Herlina1, Ace Tatang Hidayat1,2, Unang Supratman1,2, Sofa Fajriah3, Mohamad Nurul Azmi4, Yoshihito Shiono5.
Abstract
Two new dammarane-type triterpenoid fatty acid ester derivatives, 3β-oleate-20S-hydroxydammar-24-en (1) and 3β-oleate-20S,24S-epoxy-25-hydroxydammarane (2) with a known dammarane-type triterpenoid compound, such as 20S-hydroxydammar-24-en-3-on (3), were isolated from the stem bark of Aglaiaelliptica (C.DC.) Blume. The chemical structures were determined by spectroscopic methods, including FTIR, NMR (one and two-dimensional), and HRESITOF-MS analysis, as well as chemical derivatization and comparison with previous literature. Furthermore, the synthetic analog resulting from transesterification of 1 and 2 also obtained 3β,20S-dihydroxy-dammar-24-en (4) and 20S,24S-epoxy-3β,25-dihydroxydammarane (5), respectively. The cytotoxic effect of all isolated and synthetic analog compounds was evaluated using PrestoBlue reagent against MCF-7 breast cancer cell and B16-F10 melanoma cell lines. The 20S-hydroxydammar-24-en-3-on (3) showed the strongest activity against MCF-7 breast cancer and B16-F10 melanoma cell, indicating that the ketone group at C-3 in 3 plays an essential role in the cytotoxicity of dammarane-type triterpenoid. On the other hand, compounds 1 and 2 had very weak cytotoxic activity against the two cell lines, indicating the presence of fatty acid, significantly decreasing cytotoxic activity. This showed the significance of the discovery to investigate the essential structural feature in dammarane-type triterpenoid, specifically for the future development of anticancer drugs.Entities:
Keywords: Aglaia elliptica; B16-F10 cell line; MCF-7 cell line; cytotoxic activity; dammarane-type triterpenoid fatty acid ester
Mesh:
Substances:
Year: 2022 PMID: 36235298 PMCID: PMC9571388 DOI: 10.3390/molecules27196757
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Structure of compounds 1–5.
NMR Data (500 MHz for 1H and 125 MHz for 13C, in CDCl3) for 1 and 2.
| No. | 1 | 2 | ||
|---|---|---|---|---|
| 13C NMR | 1H NMR | 13C NMR | 1H NMR | |
| 1 | 32.7 (t) | 1.95 (2H, m) | 33.0 (t) | 2.21 (2H, m) |
| 2 | 24.9 (t) | 1.48 (2H, m) | 23.8 (t) | 1.68 (2H, m) |
| 3 | 80.7 (d) | 4.47 (1H, dd, 5.5, 10.5) | 80.6 (d) | 4.45 (1H, dd, 5.0, 11.0) |
| 4 | 38.0 (s) | - | 37.1 (s) | - |
| 5 | 56.0 (d) | 0.82 (1H, m) | 56.0 (d) | 0.82 (1H, m) |
| 6 | 18.2 (t) | 1.41 (2H, m) | 18.2 (t) | 1.51, 1.38 (each 1H, m) |
| 7 | 35.2 (t) | 1.22, 1.54 (each 1H, m) | 34.8 (t) | 1.65 (1H, m) |
| 8 | 40.4 (s) | - | 40.5 (s) | - |
| 9 | 50.6 (d) | 1.32 (1H, m) | 50.8 (d) | 1.32 (1H, m) |
| 10 | 37.1 (s) | - | 38.0 (s) | - |
| 11 | 21.6 (t) | 1.48 (2H, m) | 21.1 (t) | 1.51 (2H, m) |
| 12 | 25.1 (t) | 1.43 (2H, m) | 27.0 (t) | 1.76 (2H, m) |
| 13 | 42.3 (d) | 1.59 (1H, m) | 42.9 (d) | 1.61 (1H, m) |
| 14 | 50.4 (s) | - | 50.1 (s) | - |
| 15 | 31.2 (t) | 1.05 (2H, m) | 31.5 (t) | 1.04 (2H, m) |
| 16 | 27.6 (t) | 1.78 (2H, m) | 25.9 (t) | 1.25 (2H, m) |
| 17 | 49.9 (d) | 1.71 (1H, m) | 49.9 (d) | 1.85 (1H, m) |
| 18 | 15.6 (q) | 0.94 (3H, s) | 16.4 (q) | 0.85 (3H, s) |
| 19 | 16.3 (q) | 0.85 (3H, s) | 16.6 (q) | 0.87 (3H, s) |
| 20 | 75.5 (s) | - | 86.6 (s) | - |
| 21 | 25.5 (q) | 1.12 (3H, s) | 27.2 (q) | 1.12 (3H, s) |
| 22 | 40.6 (t) | 1.45 (2H, m) | 35.3 (t) | 1.26 (2H, m) |
| 23 | 22.7 (t) | 1.28 (2H, m) | 26.4 (t) | 1.74 (2H, m) |
| 24 | 124.8 (d) | 5.10 (1H, t, 7.0) | 86.3 (d) | 3.62 (1H, dd, 5.5, 10.0) |
| 25 | 131.7 (s) | - | 70.3 (s) | - |
| 26 | 25.8 (q) | 1.67 (3H, s) | 27.9 (q) | 1.17 (3H, s) |
| 27 | 17.8 (q) | 1.61 (3H, s) | 24.1 (q) | 1.09 (3H, s) |
| 28 | 28.1 (q) | 0.83 (3H, s) | 28.1 (q) | 0.82 (3H, s) |
| 29 | 16.5 (q) | 0.85 (3H, s) | 17.5 (q) | 1.16 (3H, s) |
| 30 | 16.6 (q) | 0.86 (3H, s) | 15.6 (q) | 0.95 (3H, s) |
| 1’ | 173.7 (s) | - | 173.6 (s) | - |
| 2’ | 34.2 (t) | 2.27 (2H, t, 7.5) | 34.2 (t) | 2.27 (2H, t, 7.5) |
| 3’ | 23.8 (t) | 1.59 (2H, m) | 23.8 (t) | 1.68 (2H, m) |
| 4’ | 29.2 (t) | 1.24 (2H, m) | 29.2 (t) | 1.24 (2H, m) |
| 5’ | 29.6 (t) | 1.24 (2H, m) | 29.6 (t) | 1.24 (2H, m) |
| 6’ | 29.4 (t) | 1.24 (2H, m) | 29.3 (t) | 1.24 (2H, m) |
| 7’ | 29.7 (t) | 1.24 (2H, m) | 29.7 (t) | 1.24 (2H, m) |
| 8’ | 32.0 (t) | 1.99 (2H, m) | 32.0 (t) | 2.00 (2H, m) |
| 9’ | 128.9 (d) | 5.40 (1H, dd, 3.5, 9.5) | 128.9 (d) | 5.40 (1H, dd, 3.5, 10.0) |
| 10’ | 131.8 (d) | 5.35 (1H, dd, 3.5, 9.5) | 131.7 (d) | 5.35 (1H, dd, 3.5, 10.0) |
| 11’ | 32.1 (t) | 1.99 (2H, m) | 32.1 (t) | 2.00 (2H, m) |
| 12’ | 29.4 (t) | 1.24 (2H, m) | 29.3 (t) | 1.24 (2H, m) |
| 13’ | 29.6 (t) | 1.24 (2H, m) | 29.6 (t) | 1.24 (2H, m) |
| 14’ | 29.2 (t) | 1.24 (2H, m) | 29.2 (t) | 1.24 (2H, m) |
| 15’ | 29.4 (t) | 1.24 (2H, m) | 29.3 (t) | 1.24 (2H, m) |
| 16’ | 29.7 (t) | 1.24 (2H, m) | 29.7 (t) | 1.24 (2H, m) |
| 17’ | 22.6 (t) | 1.22 (2H, m) | 22.7 (t) | 1.22 (2H, m) |
| 18’ | 14.2 (q) | 0.85 (3H, t, 6.5) | 14.2 (q) | 0.85 (3H, t, 6.5) |
Figure 2Selected HMBC and 1H–1H COSY correlations for 1 and 2.
Figure 3Selected NOESY correlations for 1 and 2.
Cytotoxic activities against MCF-7 and B16F10 cell lines for 1–5.
| Compounds | IC50 for MCF-7 (μg/mL) | IC50 for B16F10 (μg/mL) |
|---|---|---|
| 3β-oleate-20 | 313.23 | 181.34 |
| 20S,24 | 212.21 | 98.40 |
| 20 | 67.30 | 22.95 |
| 3β,20 | 121.01 | 49.57 |
| 20 | 82.61 | 95.27 |
| Cisplatin (positive control) | 53.00 | 43.00 |